9,293 Shares in Hologic, Inc. (NASDAQ:HOLX) Purchased by Bridges Investment Management Inc.

Bridges Investment Management Inc. bought a new stake in Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 9,293 shares of the medical equipment provider’s stock, valued at approximately $690,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. Innealta Capital LLC purchased a new position in Hologic in the 2nd quarter valued at about $25,000. iA Global Asset Management Inc. purchased a new position in Hologic in the 1st quarter valued at about $37,000. Cranbrook Wealth Management LLC purchased a new position in Hologic in the 2nd quarter valued at about $47,000. Mather Group LLC. purchased a new position in Hologic in the 1st quarter valued at about $48,000. Finally, Massmutual Trust Co. FSB ADV lifted its holdings in Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Down 1.2 %

HOLX opened at $81.39 on Friday. The firm has a 50 day moving average price of $80.82 and a 200 day moving average price of $77.12. The company has a market cap of $18.99 billion, a PE ratio of 41.53, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.93 EPS. Sell-side analysts expect that Hologic, Inc. will post 4.09 earnings per share for the current year.

Insider Buying and Selling

In other Hologic news, insider Brandon Schnittker sold 476 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Hologic news, insider Brandon Schnittker sold 476 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,280 shares of company stock valued at $1,469,973. 1.75% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have issued reports on HOLX. Stephens restated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Evercore ISI increased their price objective on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Tuesday, July 30th. JPMorgan Chase & Co. increased their price objective on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, September 17th. Finally, StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.60.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.